XXXX and concurrent or sequential @entity706 : Two case reports with hypersensitivity to bevacizumab and a review of the literature.

@entity1 @entity1071 @entity706 @entity5 @entity1149 @entity2 @entity900 @entity1544 @entity1200 @entity1892 @entity136
UNASSIGNED: @entity1149 ( @entity1149 ) accounts for ~80% of all cases of @entity2 , and is the leading cause of @entity5 -related mortality worldwide. The majority of @entity1149 cases of are diagnosed at an advanced stage. The outcome of @entity1 with advanced @entity1149 is poor with a median survival time of ~12 months in European and American populations. @entity1071 ( @entity1071 ) represent a heterogeneous group of expanding lymphoid cells, which occurs as a result of @entity1200 . @entity1071 are often associated with primary solid @entity5 . We report two cases of LPD diagnosed concurrently and successively to @entity1149 . The first case presents a 65-year-old female @entity1 with @entity5 , according to the International Association for the Study of Lung Cancer TNM staging system. The @entity1 developed a concurrent @entity706 and was treated with first-line therapy including six cycles of @entity136 and @entity900 , however, the @entity1 experienced an adverse drug reaction to bevacizumab, which was administered after @entity136 and prior to @entity900 . The second case presented a 74-year-old male @entity1 diagnosed with large @entity1892 . The @entity1 acheived remission of the illness, however, after one year the @entity1 was diagnosed with @entity1544 . After three years, the @entity1 underwent surgery, however disease recurrence was identified. Subsequently, the @entity1 was treated with sterotactic radiotherapy and oral chemotherapy. A review of the associated literature was also conducted.
